AbbVie (ABBV) Short-Term Debt issuances (2013 - 2026)

AbbVie (ABBV) has reported Short-Term Debt issuances for 10 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Short-Term Debt issuances rose 25.55% year-over-year to $2.0 billion in Q1 2026; TTM through Jun 2026 was $2.8 billion, a 51.1% decrease from a year earlier, with the FY2025 full-year figure at $4.8 billion, down 4.19% from the prior year.
• Short-Term Debt issuances was $2.0 billion for Q1 2026 at AbbVie, up from $791.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $5.0 billion in Q1 2024 and troughed at $791.0 million in Q3 2025.
• A 3-year average of $2.3 billion and a median of $1.8 billion in 2024 frame the typical range for Short-Term Debt issuances.
• Across the five-year window, Short-Term Debt issuances plunged 68.19% in 2025 and grew 25.55% in 2026, its largest moves.
• Over 3 years, Short-Term Debt issuances stood at $1.7 billion in 2024, then sank by 53.47% to $791.0 million in 2025, then surged by 152.84% to $2.0 billion in 2026.
• The last three Short-Term Debt issuances figures came in at $2.0 billion (Q1 2026), $791.0 million (Q3 2025), and $2.4 billion (Q2 2025), per Business Quant data.